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The prostate specific antigen (PSA) gene is a member of the human kallikrein gene family and is known 
that to be tightly regulated by androgens in the male prostate The presence of PSA is strongly 
associated with presence of steroid hormone receptors. The aim of this research was to show 
differential expression and association between steroid hormone receptors and PSA gene expression 
in breast cancer cell lines. The cell lines investigated were steroid receptor-negative breast carcinoma 
cell lines BT-20 and HBT-100 and the steroid hormone receptor-positive breast carcinoma cell lines BT-
474, ZR-75-1, MDA-MB-453 and MFM-233. Others include BG-1 (ovarian), MFE-296 (endometrium), HBT-
161 (ovarian), HBT-173 (ovarian), A-427 (lung), SK-MES-1(lung), NCI-H460(lung),MIA PaCa (pancreas), 
and Colo320 (Colon) cell lines. All cell lines were cultured as confluent and then harvested. Stimulation 
test was carried out using steroid compound. The concentration of estrogen receptor (ER) and 
progesterone receptor (PR) in all tumor cell lines were measured with the abbot enzyme immunoassay 
kit. Among cell lines tested, only steroid receptor positive cells were able to produce PSA at the protein 
and the mRNA level in response to stimulatory effects of steroid hormones. Our data suggest that the 
expression of the PSA gene in different cancer cell lines may depends on the presence of steroid 
hormone receptors. 
 





Prostate specific antigen (PSA) is a serine protease 
produced at high levels by prostate epithelial cells and 
secreted into seminal plasma. PSA is the best tumor 
marker for diagnosis and prognosis of prostatic 
carcinoma (Rekasi et al., 2001). PSA gene localized on 
chromosome 19 and has 80% sequence similarity with 
human granular kallikrein gene (Riegman et al., 1989; 
Schedlich et al., 1987; Clements, 1989). PSA is generally 
believed to be express only by prostate epithelial cells 
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demonstrated to be directly regulated by binding of and-
rogen receptor (AR) (Katerina et al., 2002). Androgen 
plays essential roles in prostate proliferation and prostate 
cancer progression (Xiaomin and Chawnshang Chang, 
2003). We have previously provided evidence that the 
PSA production was associated with the presence of 
steroid hormone receptors and this association was 
stronger between PSA and progesterone (Yu et al., 
1994). A possible explanation to the fact that PSA 
expression by breast cancer cells confers prognostic 
advantage to breast cancer patients is that its presence 
may reflect the existence of a complete hormone receptor 
pathway. According to this hypothesis, extra-prostatic 
expression of PSA may be a consequence of the 
hormone alterations presumably involved in the 
development of carcinomas, without causing any direct 
effect on the spread of cancer. It has been reported that 
PSA is detectable in ovarian cancer cytosol, primary lung 
cancer tissues, endometrium, and  other  cancer  tissues,  
 




but the frequency is much lower copared to the 
frequency of detection in breast cancer (Levesque et al., 
1995). 
From these considerations, we were promped to 
examine the possibility that steroid hormones and their 
cognate receptors could mediate production of PSA by 
non-prostatic tissues. In order to search the mechanism 
of PSA gene regulation in the non-prostatic tissues, such 
as breast, ovarian, lung and colon, we have developed a 
tissue culture system which reproduces in vitro the 
phenomenon of PSA production by these cells. Although 
BT-474 and ZR-75-1 were positive for steroid hormone 
receptors, only BT-474 breast carcinoma cell line was 
able to produce PSA in response to steroid hormones 
stimulation. The steroid hormone receptor-positive breast 
carcinoma cell line BT-474 does not produce detectable 
PSA when cultured in media devoid of steroid hormones. 
When stimulated by steroid hormones, ths cell lines 
produce PSA in a dose-response manner. We used this 
system to study the mRNA expression of PSA with and 
without stimulation. In this report, we show that 
androgens, progestins, glucocorticoids up-regulate PSA 
gene expression in breast cancer cells. In addition, we 
provide indirect evidence that the PSA gene in some 
steroid hormone receptor positive cell line and/or steroid 








All steroidal and non-steroidal compounds used in this study were 
obtained from Sigma Chemical Co., Louis, MO., except for the 
following: ICI 102,780 and casodex (ICI 176,334) (Zeneca Pharm 
INC., Mississauga, ON, Canada); RU58,668, RU54,876, RU56,187, 
nilutamide (Anandron, RU23,908) and mifepristone (RU486, 
RU38,486) (Roussel-UCLAF, Romainville, France), vitamin D 
Analogs (Ro 23-7553, and Ro 24-5531) (Hoffman-La Roche Inc, 
Nutley, Newjersy, USA), EB-1089 (Leo Pharmaceutical products 
Ltd, Allerup, denmark), LG100153, LG100272 and Degnelin 
(Ligand Pharmaceuticals Inc, san Diego, CA). Hydroxyflutamide 
was a gift from Dr. Donna peehl, Stanford University. Oral 
contraceptive (LoEsrin, Ortho 7/7/7, and Demulin) were provided 
from Park Davis, Ortho and Searle, Canada. Stock Solutions (10–2 
or 10–3 M) were prepared in absolute ethanol. More diluted 





The BT-474, ZR-75-1, MDA-MB-453 breast carcinoa cell lines, 
BG-1, HBT-75, HBT-161 ovarian carcinoma cell lines, and A-427, 
TBT-173, SK-MES-1, NCI-H460 lung tumors cell lines were 
obtained from the American type culture collection (ATCC, 
Rockville), MD. The MFE-296 endometrial cancer cells were 
obtained from Dr. R. Hackenberg, Klinikum der Philips-Universitat, 
Marburg, Germany). All breast adenocarcinoma cell lines (BT-474, 





RPMi-1640 media supplemented with glutamine (200 mmol/L), 
bovine insulin (19 mg/L), fetal bovine serum (10%), antibiotics 
(penicillin, streptomycin) and antimycotics (amphotericin B) expect 
MDA-MB-453 cell line that cultured in Lebovitz's media (GIBCO, 
BRL) supplemented with the same component above mentioned. 
The ovarian tumor cell lines (BG-1, HBT-75, and HBT-161), lung 
tumor cell lines (A-427, HBT-173, and SK-MES-1) and the 
endometrium cancer cell line, MFE-296, were maintained in RPMI-
1640 media supplemented with 10% (v/v) fetal bovine serum, 200 
mmol/L glutamine, 10 mg/L bovine insulin, antibiotics (penicillin, 
streptomycin) and antimycotics (amphotericin B). The cells were 
cultured to near confluence in plastic culture flasks and then 
transferred to phenol red-free media containing 10% charcoal-
stripped fetal bovine serum with antibiotics/antimycotics. Phenol 
red-free media were used since phenol red was found previously to 
have weak estrogenic activity (Berthois et al., 1986). And charcoal-





All tumor cell lines were then aliquoted into 24-well tissue culture 
plates (corning # 2582) and cultured to confluence with change in 
media at 3 days. Stimulations were carried out with confluent cells 
containing 2 mL of phenol red-free media with 10% charcoal-
stripped fetal calf serum and antibiotics/antimycotics. Stimulation 
was initiated by adding 2 µl of each steroid dissolved in ethanol and 
incubating for a certain period of time (usually up to 8 days). Tissue 
culture supernatant (~150 µL) was removed for PSA analysis at day 
8. Slight modifications of the protocol were introduced as 
necessary. Appropriate multiple positive and negative controls (only 
alcohol added) were included in each experiment. Wells with 
microbial contamination were excluded from the data.  
 
 
Isolation of total RNA 
 
Total RNA isolation from cell lines was performed using the TRIzol 
method (GIBCO BRL, Gaithesbul, MD, TRIzol reagent) following 
the instructions of the manufacturer. The TRIzol method is 
described briefly as follows: About 107 cells were pelleted and used 
for total RNA extraction. After incubating the samples and/or cell 
pellets for 5 min at room temperature to permit the complete 
dissociation of nucleoprotein complexes, 200 L chloroform per 1 
mL of TRIzol reagent was added into the solution. Following 
vigorous mixing, the solution was centrifuged at 12,000 x g for 15 
min at 4ºC. Centrifugation separates the diphase mixture into the 
lower red phenol-chloroform phase and upper colorless aqueous 
phase, which was removed carefully. The RNA was precipitated 
from the aqueous phase by mixing with 500 L of isopropanol per 1 
mL of initial TRIzol reagent. The samples were incubated at room 
temperature for 10 min and centrifuged at 12,000 x g for 10 min at 
4ºC. The supernatant was removed and the RNA pellet was 
washed once with 75% ethanol. After centrifugation and removal of 
the alcohol, the pellet was air dried and dissolved in diethyl 
pyrocarbonate (DCPC) treated water. The integrity of the RNA was 
checked electrophoretically, and the amount and purity by 





The synthesis of cDNA from the isolated total RNA was carried out 
with a first-strand cDNA synthesis Kit using SuperScript II reverse 
transcriptase (GIBCO BRL, Gaithersburg, MD). Briefly, 1-5 g of 






min at 70ºC , chilled on ice for 1 min and then incubated for 5 min at 
42ºC in a 19 L of reaction mixture which include 10X PCR buffer 
(containing 200 mmol/L of Tris-HCl and 500 mmol/L of KCl, pH 8.4) 
(Boehringer Mannheim), 10 mmol/L of deoxynuceotide triphosphate 
mix (Boehringer Mannheim), 10 mmol/L of dithiothretiol (DDT), and 
25 mmol/L of MgCl2 . Then, 200 units (1 L) of SuperScript II 
reverse transcriptase were added to the reaction mixture, incubated 
for 50 min at 42ºC, terminated at 70ºC for 15 min and chilled on ice. 
The mixture was then treated with 1 L of RNase H for 20 min at 
37ºC before proceeding to amplification of the target cDNA. 
Negative control reactions for RT-PCR were performed using all 





Two oligonucleotide primers were used to amplify a 754 base pair 
region of PSA cDNA. These, originally described by Deguchi et al. 
(1993) have the following sequence: PSA A1: 5'-
TGCGCAAGTTCACCCTCA-3', PSA B1: 5'-
CCCTCTCCTTACTTCATCC-3'. For actin cDNA amplification, we 
used the following primers, previously published (Okazaki, 1992). 
ACT 1: 5'-ACAATGAGCTGCGTGTGGCT-3', ACT2: 5'-
TCTCCTTAATGTCACGCACGA-3'. PCR with primers A1/B1 Yields 
a 754bp fragment, and with ACT1/ACT2 a 372 bp fragment. 
 
 
PCR Protocol   
 
PCR was performed in 0.2 mL thin-walled MicroAmp reaction tubes 
on a Perkin-Elmer Gene Amp 2400 system. Total volume was 50 
L. The reaction mixture contained PCR buffer (50 mmol/L KCl, 10 
mmol/L Tris buffer, pH 8.3, 1.5 mmol/L MgCl2, 10mg/L gelatin), 200 
mol/L of deoxynucleotide triphosphated, (dNTPs) 1 mol/L of PCR 
primers, 2.0 units of Taq DNA polymerase (Boehringer Mannheim) 
and 5 L of cDNA target (added last). The PCR was performed with 
one cycle at 94ºC for 5 min, 30 cycles with denaturation at 94ºC for 
30 s, annealing at 60ºC for 30 s and extension at 72ºC for 7 min. 20 
L of PCR reactions were electrophoresed on 2% Agarose gels and 
visualized with ethidium bromide staining. Negative controls did not 
contain template DNA. 
 
 
Labeling of PSA cDNA probe 
 
PSA cDNA plasmid was linearized with Hind III enzyme digestion 
and labeled with the random primer method by incorporation of 
digoxigenin-labeled deoxyridine triphosphate (DIG-dUTP0, 
Boehringer Mannheim) using the protocol recommended by the 
manufacturer. PSA cDNA plasmid was first incubated for 1 h at 
37ºC with 150 units of Hind-III restriction enzyme (Boehringer 
Mannheim) in a 10 mmol/L of Tris-HCl buffer, pH 8.0, containing 0.1 
mol of NaCl, 5 mmol/L of MgCl2 and 1 mmol/L of 2-
mercaptoethanol per liter. Then, the PSA cDNA plasmid was 
denatured by heating in a boiling water bath for 10 min and chilled 
on ice. 30 L of 10X concentrated dNTP mix, including 1 mmol/L of 
dATP, 1 mmol/L of dCTP, 1 mmol/L of dGTP, 0.65 mmol/L of dTTP, 
and 0.35 mmol/L of DIG-dUTP . The whole mixture was incubated 
at least 60 min at 37ºC. 
 
 
RNA labeling by in vitro transcription 
 
The PSA PCR product was cloned in to the polylinker site of the 
pCR2.1 transcription vector. The recombinant pCR2.1 transcription 
vector contains promoters for SP6 and T7 RNA  polymerizes.   After  




linearization of the vector with Hind III restriction enzyme, the T7 
RNA polymerase was used to create "run-off" transcripts using the 
DIG RNA Labeling Kit (Boehringer Mannheim, Germany) and the 
protocol recommended by the manufacture. DIG-UTP was used as 
a substrate and was incorporated into the transcript. The DIG-
labeled RNA was used as a non-radioactive probe in southern 
blots. In brief description, the following reagents were added to a 
microfuge tube on ice: 20 L of 10X transcription buffer, 20 L of 
10X concentrated NTP labeling mixture containing 10 mM ATP, 10 
mM CTP, 10 mM GTP, 6.5 mM UTP, 3.5 mM DIG-UTP, pH 7.5, 10 
g of linearized DNA, 4000 units of T7 RNA polymerase, and 10 L 
of RNase inhibitor and centrifuged briefly. The reaction mixture was 
incubated for 2 h at 37ºC. Longer incubation does not increase the 
yield of labeled RNA. DIG-labeled RNA probes have the following 
advantages: 1) they are of defined unity lengthy, 2) they are single 
strand specific and therefore 3) all labeled RNA is available for 
hybridization and does not renature as in the case of DNA. RNA, 
which is DIG-labeled according to the above protocol, allows the 
detection of 0.1 pg homologous DNA or RNA in a dot blot. 
 
 
Gel electrophoresis, Southern Blotting and hybridization 
 
Aliquots of PCR products (20 L) were electrophoresed at 100 V for 
45 min on 2% agarose minigel containing ethidium bromide. The 
gels were then southern blotted onto positively charged nylon 
membranes (Boehringer Mannheim) by overnight alkali capillary 
blotting with use of 0.4 mol/L NaOH. The membranes were then 
baked for 15-30 min at 120ºC. For hybridization, the membranes 
were placed in a roller bottle with 20 mL of hybridization buffer per 
100 cm2 of membrane. We used a commercial hybridization solution 
(DIG Easy Hyb, Boehringer Mannheim). Prehybridization was at 
42ºC for 1 h. The solution was then replaced with 5 mL per 100 cm2 
of membrane of hybridization buffer containing 50 ng/mL of freshly 
denatured labeled PSA cDNA and/or 200 ng/mL DIG-Labeled 
probes. Hybridization was carried out for 12-16 h at 42ºC. Filters 
were subsequently washed twice with 2X SSC containing 0.1% 
SDS at room temperature (5 min per wash) and twice with 0.1X 
SSC containing 0.1% SDS at 68ºC (15 min per wash). 
 
 
Detection protocol  
 
The detection was performed as follows: The membranes were first 
washed briefly in a washing buffer containing 100 mM maleic acid, 
150 mM NaCl, pH 7.5, and 0.3% Tween 20 for 1 to 5 min at room 
temperature and then were incubated in blocking solution 
(Boehringer Mannheim) for 30 min. Alkaline phosphatase-
conjugated anti-digoxigenin antibody (Fab fragment) was diluted to 
a final concentration of 53 mU/mL (5000-fold) in blocking solution. 
The membranes were incubated in diluted antibody conjugate 
solution for 30 min and then washed twice for 15 min each at room 
temperature in washing buffer. Finally membranes were 
equilibrated in a buffer containing 0.1 mol/L of Tris-HCl, 0.1 mol/L of 
NaCl and 50 mmol/L of MgCl2 pH 9.5 for 5 min at room temperature 
and incubated with 100-fold diluted chemiluminesent substrate in 
the buffer stated above, CDP-star (25 mM,Tropix, bedor, mA). 
While CDP-star equilibrating buffer was 0.1 M diethanolamine, 0.1 
mM MgCl2 pH 9.5.The chemiluminesent signal was captured on X-






The cell pellets were lysed for 30 min on ice with 1 mL of lysis 
buffer. Lysis  buffer  was  50  mmol/L  Tris,  pH  8.0  containing  150  
 




mmol/L sodium chloride 5 mmol/L ethylene diamine tetraacetic acid 
(EDTA), 10 g/L Nonidet NP-40 surfactant, 1 mmol/L 
phenylmethylsulphonyl fluoride and 1 mg/L each of aprotinin and 
leupeptin as proteinase inhibitors. The lysate was centrifuged at 
15000 g at 4ºC for 30 min; the supernatant was collected and 
immediately assayed for PSA and total protein. 
 
 
PSA measurements  
 
PSA in the cytosolic extracts and/or tissue culture supernatant were 
measured with a highly sensitive and specific time-resolved 
immunofluorometric technique previously established and 
described in detail elsewhere (Ferguson et al., 1996). In brief, the 
PSA assay uses a mouse monoclonal anti-PSA capture antibody 
coated to polystyrene microtiter wells, a biotinylated monoclonal 
anti-PSA detection an antibody and alkaline phosphatase-labeled 
streptavidin (SA-ALP). In this immunoassay, 100 L of sample is 
incubated with the coating antibody in the presence of 50 L of 
assay buffer containing the monoclonal biotinylated anti-PSA 
detection antibody. After 1 h incubation followed by washing X6, the 
SA-ALP conjugate is added for 15 min followed by another washing 
X6. The activity of ALP is the measured by adding the substrate 5'-
fluorosalicyl phosphate, incubating for 10 min and then by adding a 
Tb3+ and EDTA-containing developing solution. After 2 min, the 
fluorescence is measured in the time resolved fluorometric mode 
with the CyberFlour-615 immunoanalyzer (CyberFluor Inc., Toronto, 
Ontario). This assay has a detection limit of 1 ng/L of PSA and can 
measure PSA at levels of 1 ng/L or higher (up to 10000 ng/L) with a 
precision of <10%. All assays were performed in duplicate. Tissue 
culture supernatants and/or tumor cytosolic extracts were measured 




Measurement of steroid hormone receptor 
 
The concentration (fmol/mg) of estrogen receptor (ER) and 
progesterone receptor (PR) in all tumor cell lines were measured 
with the Abbott enzyme immunoassay kit (Abbott laboratories, 





Different carcinoma cell lines were first measured for the 
presence of the steroid hormone receptors, estrogen and 
progesterone receptor (ER and PR). The cell line, tissue 
of origin, ER and PR concentrations (fmol per mg of total 
protein) were summarized in Table 1. 
In order to investigate the mechanism of differential 
expression and regulation of PSA gene stimulation 
experiments were further conducted using the steroid 
receptor-negative breast carcinoma cell lines BT-20, 
HBT-100, and the steroid hormone receptor-positive 
carcinoma cell lines BT-474, ZR-75-1, MDA-MB-453, and 
MFM-233. The same experiment was carried out using 
BG-1 (ovarian) MFE-296 (endometrium), HBT-161 
(ovarian), HBT-173 (lung), A-427 (lung), SK-MES-1 
(lung), NCI-H460 (lung), MIA PaCa (pancreas), and 
Colo320 (Colon) cell lines. None of the compounds was 

















Figure 1. RT-PCR for mRNA extracted from BT-474 cell line. M: 
molecular weight markers. Sizes in base pairs (bp) are shown in 
left panel. Lane 1. PCR negative control (no template added). 
Lanes 2-4 are positive for PSA mRNA. Lanes 6-10. RT-PCR for 








404 bp  
 
Figure 2. RT-PCR for mRNA extracted from HBT-173 cell 
line. M: Molecular weight. Lanes: (1) HBT-173, (2) BT-20, (3) 
HBT161, (4) A-427, (5) SK-MES-1, (6) HBT-75, (7) HBL-100 
and lanes 8-9 are negative control. 
 
 
all the carcinoma cell lines (Table 1) tested for PSA 
production, only steroid hormone receptor positive breast 
carcinoma BT-474, ZR-75-1 and MDA-MB-453 cell lines 
were able to produce PSA at the protein and the mRNA 
level in response to stimulatory effects of steroid 
hormones. And among steroid receptor positive cell lines, 
BT-474 had strong response to stimulatory effect at the 
protein and mRNA level rather than ZR-75-1 and MDA-
MB-453 which were detected only  on southern blot 
hybridization (Figures 1 and 3). Therefore, we were able 
to establish a highly sensitive tissue culture system which 
produces the phenomenon of PSA production by breast 
cells. The breast carcinoma BT-474 cell line was cultured 
in the absence of any stimulating steroid and in the 
presence of the stimulating steroid norgestrel at a 





The PSA gene is a member of the human kallikrein gene 
family and is known to be tightly regulated by androgens 
in the male prostate (Ojasoo et al., 1988; Glover and 
Darber, 1989). The epithelial cells of the prostate gland 
are rich in AR and some stromal cells also contain AR  as  




Table 1. Steroid hormone receptor levels in cell lines tested for PSA production. 
 
No. Cell lines Tissue of origin 
Estrogen receptor (ER) 
(f mol/mg) 
Progesterone receptor 
(PR)  (f mol/mg) 
1. ZR-75-1 Breast 112 482 
2. MDA-MB-453 Breast 0 0 
3. BT-474 Breast 29 389 
4. MFM-233 Breast 1 1 
5. HBL-100 Breast 0 0 
6. BT-20 Breast 0 0 
7. BG-1 Ovarian 36 420 
8. HBT-75 Ovarian 0 1 
9. HBT-161 Ovarian N/A N/a (2) 
10. HBT-173 Lung 1 3 
11. A-427 Lung 0 1 
12. SK-MES-1 Lung N/A N/A 
13. NCI-H460 Lung N/A N/A 
14. MFE-296 Endometrium 1 1 
15. MIA PaCa Pancreas 1 0 
16. Colo 320 colon 1 0 
                                  
 
 





Figure 3. PCR products were run on an agarose gel, Southern-blotted and hybridized with a DIG-labeled RNA probe. (A) M, 
Biotinylated molecular weight markers; lanes 1 to 6, MDA-453 cells were stimulated with testostrone, estrogen, B-estradiol, 
tamoxifen, triaminolone acetonide, norgestrel, respectively;  Lane 7, positive control; Lane 8, negative control. (B) M, Biotinylated 
molecular weight markers. Lanes 1 to 7, RZ-75-1 cells were stimulated with testostrone, norgestrel, aldostrone, triaminolone 




well as the enzyme 5-reductase, which reduces 
testosterone to dihydrotestosterone (Ojasoo et al., 1988). 
The PSA gene has an HRE to which the activated AR 
binds (Glover and Darber, 1989; Nordeen et al., 1989; 
Kafrissen, 1992; Murtha et al., 1993; Smith et al., 1995). 
The PSA gene is up-regulated by androgens and 
androgen agonists and is down regulated by 
antiandrogens. 
Various non-prostatic carcinoma cell lines were first 
cultured and measured for the presence of steroid 
hormone receptors, ER and PR. Further using tissue 
culture system these cell lines were tested for PSA 
production. We have shown that the steroid hormone 
receptor-positive breast carcinoma cell line BT-474 is 
capable of producing PSA protein under appropriating 
stimulation by steroid hormones. T47-D and MCF-7 cells 
do not produce PSA at the protein and mRNA level in the 
absence of steroid hormones (Diamandis et al., 1994; Yu 
et al., 1994). However, BT-474, ZR-75-1, and MDA-MB-
453 do not produce PSA protein but constitutively 
express PSA mRNA in the absence of any stimulation 
(Figures 1 and 3). The PSA mRNA produced by BT-474 
cells is identical to the sequence of PSA mRNA from 
prostate cells. In contrast, the breast carcinoma cell line 
BT-20, which is devoid of steroid hormone receptors did 
not produce PSA after stimulation. We have thus 
postulated that PSA production by breast cells is 
dependent on the steroid hormone/steroid hormone 
receptor system. We further demonstrated that the 
receptors and hormones are necessary but not sufficient 
for PSA production. When we stimulated the steroid 
hormone  receptor-positive  cell   lines   ZR-75-1   (breast  
 




carcinoma) none was able to induce PSA production. The 
presence of estrogen and progesterone receptors in 
these cell lines was confirmed by analysis with 
established enzyme immunoassay kit (Table 1).  
Apparently, either post-receptor defect is present in 
these cell lines is tissue specific. These possibilities were 
not studied further. 
Taken together, our data suggest the following: The 
breast carcinoma cell line BT-474 has the necessary 
receptors and other transcriptional machinery to produce 
PSA. Once stimulated by a steroid hormone, Bt-474 cells 
synthesize detectable intracellular protein within 8 h and 
secrete detectable protein within 24 h. PSA gene 
regulation is under the control of androgens and 
progestins through the independent action of the 
androgen and progesterone receptors (positive 
regulation). Our data, showing multihormone regulation of 
the PSA gene, are in accord with those of Glover and 
Darbe (1989) and Zava et al. (1979) who concluded the 
same using T-47D cells transfected with the mammary 
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